Advanced Search
Select a search constraint:
The application of Chlorag+ard utilizes a proprietary process whereby chlorhexidine is chemically bonded to the catheter surface, providing a controlled release of the antimicrobial agent. Chlorag+ard is designed to reduce colonization of pathogens responsible for causing central line–associated bloodstream infections (CLABSIs).
Chlorag+ard technology complements your facility's efforts toward attaining and sustaining zero CLABSIs by protecting the catheter surfaces where pathogens attach.
Meets the latest stringent regulatory requirements for antimicrobial devices and achieves a 4-log10 reduction, with only 1 in 10,000 surviving organisms.1
| Base-10 logarithmic system | Reduction | Surviving organisms | Examples |
|---|---|---|---|
| 1-log reduction | 90% | 1 in 10 | NA |
| 2-log reduction | 99% | 1 in 100 | NA |
| 3-log reduction | 99.9% | 1 in 1000 | ChloraPrep® |
| 4-log reduction | 99.99% | 1 in 10,000 | Chlorag+ard* |
* Chlorag+ard and ChloraPrep provide effective antimicrobial protection in different environments.
To learn more about the benefits of Chlorag+ard technology, download the Chlorag+ard Technology Information Sheet. (
PDF 400k)
†MRSE = methicillin-resistant Staphylococcus epidermidis; VRE = vancomycin-resistant enterococci; MRSA = methicillin-resistant Staphylococcus aureus; MSSE = methicillin-sensitive Staphylococcus epidermidis; MSSA = methicillin-sensitive Staphylococcus aureus.
Reference: 1. Data on file, Teleflex Incorporated.
ChloraPrep is a registered trademark of CareFusion Corporation.
Teleflex, ArrowEVOLUTION, Chlorag+ard and ZERO ZONE are trademarks or registered trademarks of Teleflex Incorporated or its affiliates.